Neogen Chemicals Reports FY26 Standalone PAT of ₹46.96 Cr; Expansion Projects Delayed

Neogen Chemicals Limited has reported its audited financial results for the fiscal year ended March 31, 2026. On a standalone basis, the company recorded a profit after tax (PAT) of ₹46.96 crore on revenues of ₹871.31 crore. For the same period, consolidated figures showed PAT at ₹28.75 crore on revenues of ₹868.10 crore.

The company's Board of Directors has recommended a final dividend of Re. 1 per equity share for FY 2025-26.

Significant revisions were announced for its subsidiary, Neogen Ionics Limited, concerning the Dahej and Pakhajan manufacturing facilities. The Dahej Phase 1 project's cost has been revised to ₹428 crore, with completion now targeted for February 2027. The Pakhajan Phase 2 project is now estimated at ₹1,367 crore, aiming for completion by March 2027. These adjustments bring the total estimated capital outlay for both projects combined to ₹1,795 crore. Outstanding qualified borrowings stood at ₹321.52 crore as of March 31, 2026.

These revised timelines mean Neogen Chemicals' expanded specialty chemical manufacturing capacity will come online later than initially planned. This shift impacts the expected revenue ramp-up and the phasing of capital expenditures.

Neogen Chemicals, a key player in India's specialty chemical sector, relies on such large-scale expansion projects to bolster manufacturing capabilities and meet growing demand. Revisions in project timelines are common and can stem from evolving project requirements, design optimizations, or efforts to increase the localization of raw materials.

Project execution risks, including potential further delays, cost overruns, and challenges in achieving operational efficiencies, are inherent in these large chemical plant expansions. Investors will closely monitor the progress of the Dahej and Pakhajan projects.

The company operates within a competitive specialty chemicals market, where peers like Aarti Industries and Vinati Organics are also focused on expanding capacities and product portfolios. Success for these expansions typically depends on market demand, technological efficiency, and robust project management.

Shareholders will vote on the recommended final dividend at the upcoming Annual General Meeting (AGM). Key items for investors to track include the dividend approval, the record date, and quarterly financial results to monitor revenue generation and expansion project progress.